Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Sanofi : Signs Agreement with Principia Biopharma for MS Drug Candidate

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 01:15pm CEST

By Sonia Amaral Rohter

Sanofi SA (SAN.FR) on Thursday said that it has signed a license agreement with Principia Biopharma Inc. to develop an experimental oral treatment for multiple sclerosis, or MS, as part of its efforts to expand its MS franchise.

Under the terms of the deal, Sanofi will be granted an exclusive, worldwide license to develop and commercialize the drug, which is currently under clinical development. Sanofi will make an upfront payment of $40 million to Principia, and Principia will receive future milestone payments of up to $765 million as well as royalties on product sales.

According to the company, the drug candidate, referred to as PRN2246, shows promise in treating MS, a chronic inflammatory disorder of the central nervous system that affects over 2.5 million people worldwide. Principia has recently initiated a phase 1 trial of PRN2246 in healthy volunteers, according to the release.

Sanofi already has two MS medicines on the market, Aubagio and Lemtrada, as well as an in-house research and development program to address MS and other neurological diseases.

"Our agreement with Principia is an example of Sanofi's strategic commitment to build our drug discovery and development pipeline in MS and neurological diseases," says Rita Balice-Gordon, global head of the company's MS/neuroscience therapeutic research area. "Complementing our own internal R&D expertise, external relationships like this may accelerate delivery of new treatments to patients living with these serious diseases."

The transaction, which is subject to customary regulatory approvals, is expected to close in the fourth quarter.

Write to Sonia Amaral Rohter at sonia.amaralrohter@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
10/17AIMMUNE THERAPEUTICS : Announces Initiation of Phase 2 Study With Regeneron and ..
10/17REGENERON PHARMACEUTICALS : Dupixent (dupilumab) Showed Positive Topline Results..
10/17GLOBAL MARKETS LIVE : Netflix, Danone, Sanofi, Tesla...
10/17SANOFI : others tackle diabetes burden in Nigeria
10/17PRINCIPIA BIOPHARMA : Achieves $10 Million in Additional Milestones Related to D..
10/17CANADIANS ARE INVITED TO JOIN THE CO : Raise Your Hand for Diabetes
10/17Minnesota attorney-general accuses insulin makers of deceptive drug pricing
10/16SANOFI : Dupixent® (dupilumab) showed positive topline results in two Phase 3 tr..
10/16SANOFI : ICER weighing issuing advice on trial design
10/16Insulin Delivery Devices Market to 2023 - Top Key Players Novo, Nordisk, Sano..
More news
News from SeekingAlpha
10/17Johnson & Johnson suspends clinical development of antiviral lumicitabine 
10/17With 5 Months To Go, Brexit Hangs In The Balance (Wall Street Breakfast Podca.. 
10/17WALL STREET BREAKFAST : Crunch Time At Brexit Summit 
10/17DUPIXENT : Top-Down And Bottom-Up Perspectives On The News 
10/17Latest concerns about rising drug costs 
At a crossroads
Financials (€)
Sales 2018 35 046 M
EBIT 2018 8 389 M
Net income 2018 4 995 M
Debt 2018 16 265 M
Yield 2018 3,93%
P/E ratio 2018 18,49
P/E ratio 2019 17,22
EV / Sales 2018 3,15x
EV / Sales 2019 3,04x
Capitalization 94 123 M
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 80,0 €
Spread / Average Target 4,7%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Executive Vice President-Medical Affairs
John C. Reed Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI4.79%108 740
JOHNSON & JOHNSON-4.19%359 141
PFIZER20.87%256 643
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 777
MERCK AND COMPANY23.44%185 661